Biggest News Aggregation in the World
📰 Risk Evaluation News

Page 7 - Risk Evaluation News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.

Stein, lawmakers square off again in abortion pill lawsuit filings

State Attorney General Josh Stein and Republican state legislative leaders offered a federal judge opposing arguments this week in a lawsuit challenging North Carolina’s abortion pill restrictions. US District Judge Catherine Eagles asked parties in the case, Bryant v. Stein, to submit briefs Monday. Eagles will render a decision in the case without holding a trial.
North Carolina United States Tim Moore Josh Stein Amy Bryant Catherine Eagles

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated ...
United States Stanford University Foster City Santa Monica Chris Mcdonald David Miklos

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL) -January 30, 2024 at 07:00 am EST

U.S. FDA grants both FL and MCL applications Priority Review Applications based on results from TRANSCEND FL and TRANSCEND NHL 001, in which Breyanzi demonstrated clinically meaningful benefit with...
United States United Kingdom Bristol Myers Squibb Anne Kerber Exchange Commission Drug Administration

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel)in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

PRINCETON - Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization approval of Abecma for...
United States United Kingdom Great Britain Bristol Myers Squibb Anne Kerber Hemophagocytic Lymphohistiocytosis

Amgen Osteoporosis Drug Prolia Is Hit With FDA's Strictest Warning

The FDA said Amgen’s Prolia may lead to low levels of calcium, or hypocalcemia. The osteoporosis drug’s black box warning follows an FDA review of Centers for Medicare & Medicaid Services studies that found Prolia led to a significant increase in the risk of severe hypocalcemia compared to treatment with an older class of medicines.
Bio Zynteglo Eli Lilly Forteo Radius Health Centers For Medicare Medicaid Services European Commission Vertex Pharmaceuticals

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science